Vertex to Acquire Crinetics in $10 Billion Bet on Rare Endocrine Therapies
Vertex will spend $10 billion to acquire Crinetics Pharmaceuticals, its largest-ever deal, expanding Vertex's portfolio in rare endocrine disorder therapies and signaling a major strategic move in biotech mergers and acquisitions.